6 Results for "

IRAK4-IN-7

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "IRAK4-IN-7" in MCE Product Catalog:

Cat. No.: HY-109585
CAS No.: 1801343-74-7
Purity:  99.36%
Target:  

IRAK

Research Areas:  

Inflammation/Immunology Cancer

IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145483
CAS No.: 2432994-31-3
Purity:  99.77%
Synonyms: KYM-001; PROTAC IRAK4 degrader-7
Target:  

PROTACs IRAK Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150741
CAS No.: 332437-00-0
Purity:  97.92%
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150741C
Purity:  97.92%
Research Areas:  

Cancer

ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 + T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 + T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 + T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145483A
CAS No.: 2751703-31-6
Synonyms: KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride
Target:  

PROTACs IRAK Apoptosis

Research Areas:  

Inflammation/Immunology

KT-474 (KYM-001; PROTAC IRAK4 degrader-7) hydrochloride is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL .
loading...
    loading...
Cat. No.: HY-109585R
CAS No.: 1801343-74-7
Research Areas:  

Inflammation/Immunology Cancer

IRAK4-IN-7 (Standard) is the analytical standard of IRAK4-IN-7 (HY-109585). This product is intended for research and analytical applications. IRAK4-IN-7 is a selective, potent and orally active interleuKin-1 receptor-associated Kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .
loading...
    loading...